Ferumoxytol magnetic resonance angiography: a dose-finding study in patients with chronic kidney disease.

ABSTRACT:

Objectives

Ferumoxytol is an alternative to gadolinium-based compounds as a vascular contrast agent for magnetic resonance angiography (MRA), particularly for patients with chronic kidney disease (CKD). However, dose-related efficacy data are lacking. We aimed to determine the optimal (minimum effective) dose of ferumoxytol for MRA in patients with CKD.

Methods

Ferumoxytol-enhanced MRA (FeMRA) was performed at 3.0 T in patients with CKD after dose increments up to a total of 4 mg/kg. Image quality was assessed by contrast-to-noise ratio (CNR) and signal-to-noise ratio (SNR) in the abdominal aorta and inferior vena cava. Quadratic regression analyses were performed to estimate the effects of dose increments on CNR and SNR.

Results

Twenty-three patients underwent FeMRA

SUBMITTER: Stoumpos S 

PROVIDER: S-EPMC6554242 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature